A new trading day began on Monday, with Dianthus Therapeutics Inc (NASDAQ: DNTH) stock price down -7.03% from the previous day of trading, before settling in for the closing price of $39.68. DNTH’s price has ranged from $13.36 to $45.46 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 40.14% over the past five years. Meanwhile, its annual earnings per share averaged -45.15%. With a float of $36.43 million, this company’s outstanding shares have now reached $42.85 million.
Dianthus Therapeutics Inc (DNTH) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Dianthus Therapeutics Inc is 15.04%, while institutional ownership is 92.68%. The most recent insider transaction that took place on Dec 04 ’25, was worth 903,600. In this transaction CFO & CBO of this company sold 20,000 shares at a rate of $45.18, taking the stock ownership to the 0 shares. Before that another transaction happened on Dec 04 ’25, when Company’s Officer proposed sale 20,000 for $43.97, making the entire transaction worth $879,400.
Dianthus Therapeutics Inc (DNTH) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.7 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -45.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -17.45% during the next five years compared to 40.14% growth over the previous five years of trading.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Trading Performance Indicators
Here are Dianthus Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 513.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.49, a number that is poised to hit -1.07 in the next quarter and is forecasted to reach -3.63 in one year’s time.
Technical Analysis of Dianthus Therapeutics Inc (DNTH)
Dianthus Therapeutics Inc (NASDAQ: DNTH) saw its 5-day average volume 0.48 million, a negative change from its year-to-date volume of 0.64 million. As of the previous 9 days, the stock’s Stochastic %D was 13.38%.
During the past 100 days, Dianthus Therapeutics Inc’s (DNTH) raw stochastic average was set at 66.68%, which indicates a significant increase from 8.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.93 in the past 14 days, which was lower than the 2.07 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.83, while its 200-day Moving Average is $27.55. Nevertheless, the first resistance level for the watch stands at $39.70 in the near term. At $42.51, the stock is likely to face the second major resistance level. The third major resistance level sits at $44.26. If the price goes on to break the first support level at $35.15, it is likely to go to the next support level at $33.40. The third support level lies at $30.59 if the price breaches the second support level.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Key Stats
With a market capitalization of 1.58 billion, the company has a total of 42,876K Shares Outstanding. Currently, annual sales are 6,240 K while annual income is -84,970 K. The company’s previous quarter sales were 400 K while its latest quarter income was -36,770 K.
